Each month our editorial team sifts through hundreds of papers and curates notable findings—for practitioners and informed readers who want to stay current with the evidence. Subscribe to the monthly Research Digest for expert analysis and concise summaries of key papers.
Researchers are actively testing psilocybin (the active part of “magic mushrooms”) as a possible treatment for several mental health problems. Early clinical trials—usually done under medical supervision with therapy before and after the drug session—have found quick improvements in some people with major depression, anxiety linked to serious illness, and other hard-to-treat conditions (but the studies are still small). (15135,15063,15056) Scientists propose several ways psilocybin might help, such as changing how brain networks communicate, boosting the brain’s ability to form new connections, and lowering brain inflammation. However, the exact reasons are not settled. Safety in careful clinical settings looks acceptable so far, but harms may be underreported, and unsupervised use can carry real risks. More and larger trials are needed, and many groups (for example people of color) were not well represented in early studies. (15132,15050,15135,15061,15095,15056)
This randomized, double‑blind, cross‑over trial gave 51 patients with life‑threatening cancer two sessions of psilocybin (one very low dose and one high dose) spaced five weeks apart. The high dose (22–30 mg/70 kg) produced large drops in clinician‑ and self‑rated depression and anxiety, and increased quality of life, meaning, and…
Researchers surveyed counseling professionals about psychedelics and psychedelic‑assisted therapy. They found that counselors had mixed feelings overall, but were more accepting when use was medically supervised. Most counselors said these therapies show promise and that more research is needed. The study matters because drugs like MDMA and psilocybin may soon…
This paper is a first look at whether the fast-acting psychedelic 5‑MeO‑DMT might help people with alcohol use disorder. The authors reviewed existing studies in humans and animals and found early signs that 5‑MeO‑DMT can cause intense mystical feelings and a loss of self-boundaries, and that it changes brain rhythms…
This paper is a position review that looks at three drugs—SSRIs (a common antidepressant), psilocybin (a psychedelic), and MDMA—and how they change brain circuits that use serotonin. The authors note that all three are already used or being tested as treatments for post-traumatic stress disorder (PTSD). They say we still…
